DK3252068T3 - Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro - Google Patents

Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro

Info

Publication number
DK3252068T3
DK3252068T3 DK17175771.9T DK17175771T DK3252068T3 DK 3252068 T3 DK3252068 T3 DK 3252068T3 DK 17175771 T DK17175771 T DK 17175771T DK 3252068 T3 DK3252068 T3 DK 3252068T3
Authority
DK
Denmark
Prior art keywords
oligonucleotide
vitro
vivo
compositions
methods
Prior art date
Application number
DK17175771.9T
Other languages
English (en)
Inventor
Larry J Smith
Original Assignee
Larry J Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Larry J Smith filed Critical Larry J Smith
Application granted granted Critical
Publication of DK3252068T3 publication Critical patent/DK3252068T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17175771.9T 2009-10-12 2010-10-12 Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro DK3252068T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25071409P 2009-10-12 2009-10-12
EP10823978.1A EP2488210A4 (en) 2009-10-12 2010-10-12 METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS

Publications (1)

Publication Number Publication Date
DK3252068T3 true DK3252068T3 (da) 2025-08-25

Family

ID=43876835

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17175771.9T DK3252068T3 (da) 2009-10-12 2010-10-12 Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro

Country Status (6)

Country Link
US (1) US20130079382A1 (da)
EP (3) EP3252068B1 (da)
AU (4) AU2010306940A1 (da)
CA (1) CA2780741C (da)
DK (1) DK3252068T3 (da)
WO (1) WO2011046983A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2699271A4 (en) * 2011-04-20 2015-10-07 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY
US20140051637A1 (en) * 2011-04-28 2014-02-20 National University Corporation Nagoya University Brain-targeting functional nucleic acid and use thereof
ES2707232T3 (es) * 2011-12-16 2019-04-03 Univ Nat Corp Tokyo Medical & Dental Acido nucleico bicatenario quimérico
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
KR101515210B1 (ko) 2013-07-29 2015-04-27 가톨릭대학교 산학협력단 간 섬유화 진단용 바이오마커 elk3
US11021502B2 (en) * 2014-08-04 2021-06-01 The Trustees Of The University Of Pennsylvania Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)
EP4710943A3 (en) 2015-08-28 2026-04-29 Molecular Transfer, Inc. Transfection complexes and methods of using the same
IL314908A (en) 2018-03-29 2024-10-01 Technion Res & Dev Foundation Vesicles comprising a pten inhibitor and uses of same
MX2021001282A (es) * 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos al músculo y sus usos.
US20220016156A1 (en) * 2018-12-05 2022-01-20 Nitto Denko Corporation Rnai molecule for treating cancer
CN114716518A (zh) * 2021-01-06 2022-07-08 圣诺制药公司 一种能够抑制pcsk9表达的分子构造及药物组合物
CN115044590B (zh) * 2022-06-30 2023-08-15 昆明理工大学 p53基因突变体及其表达的蛋白在制备诊断和治疗肥厚型心肌病的药物中的应用

Family Cites Families (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5378841A (en) 1989-12-20 1995-01-03 Antivirals Inc. Alpha-morpholino ribonucleoside derivatives and polymers thereof
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6783931B1 (en) 1990-01-11 2004-08-31 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
AU681997B2 (en) 1991-09-05 1997-09-18 University Of Connecticut, The Targeted delivery of poly- or oligonucleotides to cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
EP0724447B1 (en) 1991-10-24 2003-05-07 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake
US6172208B1 (en) 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
CA2170869C (en) 1993-09-03 1999-09-14 Phillip Dan Cook Amine-derivatized nucleosides and oligonucleosides
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5728399A (en) 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
AU705644B2 (en) 1995-08-01 1999-05-27 Novartis Ag Liposomal oligonucleotide compositions
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
EP1281718A3 (en) 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptides which enhance transport across tissues
WO1997023236A1 (en) 1995-12-13 1997-07-03 President And Fellows Of Harvard College Use of toxin peptides and/or affinity handles for the delivering compounds into cells
US8217015B2 (en) 2003-04-04 2012-07-10 Arrowhead Madison Inc. Endosomolytic polymers
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6737512B2 (en) 1996-06-06 2004-05-18 Isis Pharmaceuticals, Inc. Human RNase III and compositions and uses thereof
AU8269898A (en) 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999007723A1 (en) 1997-08-07 1999-02-18 University Of Maryland, Baltimore Nucleic acid uptake and release vehicle
US20080255066A1 (en) * 1997-09-23 2008-10-16 Sarissa Inc. Antisense oligonucleotide strategies for the enhancement of cancer therapies
DE19743135A1 (de) 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologisch verträgliche niedermolekular Polyethylenimine
EP2138191A1 (en) 1998-01-05 2009-12-30 University Of Washington Enhanced transport using membrane disruptive agents
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
AU768542C (en) 1998-04-08 2004-06-17 Celltech R & D Limited Lipids
JP2002512808A (ja) 1998-04-28 2002-05-08 ワシントン ユニバーシティー 融合タンパク質の形質導入法
WO1999060012A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6841539B1 (en) 1998-05-21 2005-01-11 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
EP1137664A2 (en) 1998-12-10 2001-10-04 Washington University Protein transduction system and methods of use thereof
WO2000046384A1 (en) 1999-02-08 2000-08-10 University Of Maryland, Baltimore Nucleic acid uptake and release vehicle
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
CA2364690A1 (en) 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
EP1173224B1 (en) 1999-04-02 2006-09-06 Research Development Foundation Polyethyleneimine:dna formulations for aerosol delivery
US6303573B1 (en) 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
US8211468B2 (en) 1999-06-07 2012-07-03 Arrowhead Madison Inc. Endosomolytic polymers
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
CA2391348A1 (en) 1999-07-29 2001-02-08 Assem Ziady Enhanced delivery via serpin enzyme complex receptor
EP1207909A2 (en) 1999-08-27 2002-05-29 Medical Research Council Method for coupling molecules
EP1210362A2 (en) 1999-09-01 2002-06-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
AU2281201A (en) 1999-12-29 2001-07-09 A. James Mixson Histidine copolymer and methods for using same
TWI303663B (en) 2000-02-02 2008-12-01 Kaneda Yasufumi Inactivated virus envelope
EP2348047A1 (en) 2000-04-21 2011-07-27 New England Medical Center G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US6464959B1 (en) 2000-05-01 2002-10-15 Aeropharm Technology Incorporated Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
US6468507B1 (en) 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US6610272B1 (en) 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
WO2001083740A2 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
US6492328B2 (en) 2000-06-28 2002-12-10 The University Of Iowa Research Foundation Novispirins: antimicrobial peptides
US6669959B1 (en) 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
WO2002005785A1 (en) 2000-07-18 2002-01-24 Aeropharm Technology Incorporated Modulated release therapeutic aerosols
US6841535B2 (en) 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
US6982252B2 (en) 2000-12-04 2006-01-03 Memorial Sloan-Kettering Cancer Center Inhibition of vacuolar proton ATPase activity and/or the modulation of acidic organelle function sensitizes cells to radiation, chemotherapy and biological agents
WO2002079417A2 (en) 2001-03-28 2002-10-10 President And Fellows Of Harvard College Methods of delivery of exogenous proteins to the cytosol and uses thereof
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
EP1572067A4 (en) 2001-05-18 2009-05-13 Sirna Therapeutics Inc CONJUGATES AND COMPOSITIONS FOR CELLULAR RELEASE
US20050119212A1 (en) 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20030148928A1 (en) 2001-07-20 2003-08-07 Leonid Beigelman Enzymatic nucleic acid peptide conjugates
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
CA2476468A1 (en) 2002-02-13 2003-08-21 Medbridge, Inc. Protein carrier system for therapeutic oligonucleotides
US7208314B2 (en) 2002-02-26 2007-04-24 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
AU2003224808A1 (en) 2002-03-28 2003-10-13 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
WO2003097671A1 (en) 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
US20030235818A1 (en) 2002-04-08 2003-12-25 Vsevolod Katritch Immunogenic peptides, and method of identifying same
AU2003266014B2 (en) 2002-05-06 2009-05-14 Alnylam Pharmaceuticals, Inc. Methods for delivery of nucleic acids
WO2003094973A1 (de) 2002-05-08 2003-11-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mittel und verfahren zum transport von biologisch aktiven molekülen in zellen
ES2328031T3 (es) 2002-05-24 2009-11-06 F. Hoffmann-La Roche Ag Composiciones para distribuir acidos nucleicos a celulas.
IL150087A0 (en) 2002-06-06 2002-12-01 Yissum Res Dev Co Dermaseptin-derived peptides and their use in delivery systems
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US6878805B2 (en) 2002-08-16 2005-04-12 Isis Pharmaceuticals, Inc. Peptide-conjugated oligomeric compounds
AU2003257675A1 (en) 2002-08-27 2004-05-04 Anges Mg Inc Biomolecule transfer method using virus envelope and composition and system therefor
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
WO2004020588A2 (en) 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
US20060128614A1 (en) 2002-09-20 2006-06-15 Jya-Wei Cheng Antimicrobial peptides with reduced hemolysis and methods of their use
US20040072990A1 (en) 2002-09-20 2004-04-15 Shiou-Ru Tzeng Antimicrobial peptides with reduced hemolysis and methods of their use
JP2006512906A (ja) 2002-09-28 2006-04-20 マサチューセッツ インスティチュート オブ テクノロジー インフルエンザ治療剤
WO2004043979A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7465708B2 (en) 2002-11-25 2008-12-16 Mixson A James Branched cationic copolymers and methods for antimicrobial use
ATE465255T1 (de) 2002-11-26 2010-05-15 Univ Massachusetts Verabreichung von sirnas
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
SG129240A1 (en) 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
WO2005007854A2 (en) 2003-07-09 2005-01-27 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20050222009A1 (en) 2003-10-14 2005-10-06 Itschak Lamensdorf Dual phase - PNA conjugates for the delivery of PNA through the blood brain barrier
US7776823B2 (en) 2003-10-21 2010-08-17 The Regents Of The University Of California Human cathelicidin antimicrobial peptides
CN1878789A (zh) 2003-10-21 2006-12-13 加利福尼亚大学董事会 人凯萨林菌素抗微生物肽
US20080227733A1 (en) 2003-10-30 2008-09-18 Immune Disease Institute, Inc. Method for Treating and Preventing Ischemia-Reperfusion Injury Using Rna Interfering Agent
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
WO2005074966A1 (en) 2004-02-06 2005-08-18 Adelaide Research & Innovation Pty. Ltd. A method of modulating cellular uptake and molecules useful for same
US20050260755A1 (en) * 2004-04-06 2005-11-24 Isis Pharmaceuticals, Inc. Sequential delivery of oligomeric compounds
US7399727B2 (en) 2004-04-23 2008-07-15 Saudi Basic Industries Corporation Zeolite catalyst and method
US8168600B2 (en) 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US7514530B2 (en) 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2005120152A2 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
AU2005252699B2 (en) 2004-06-07 2010-12-23 Macrogenics West, Inc. Transferrin receptor antibodies
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
WO2006091233A2 (en) 2004-07-23 2006-08-31 Boston Medical Center Corporation Cellular delivery of reagents that inhibit gene expression utilizing the anthrax toxin protective antigen (pa)
CA2504363A1 (en) 2004-07-27 2006-01-27 Daniel Grenon Adjustable and transportable scaffolding
EP1621205A1 (en) 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
DK1786472T3 (da) 2004-08-10 2013-04-15 Genzyme Corp Antisense-modulering af apolipoprotein B-ekspression
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
US20080051323A1 (en) 2004-08-21 2008-02-28 Kosak Kenneth M Chloroquine drug compositions and methods for their synthesis
US7271239B2 (en) 2004-09-01 2007-09-18 The Research Foundation Of State University Of New York D-isomers of antimicrobial peptide
WO2006029078A2 (en) 2004-09-07 2006-03-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
US20090203132A1 (en) 2004-09-09 2009-08-13 Swayze Eric E Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
NZ572403A (en) 2004-09-24 2010-03-26 Alnylam Pharmaceuticals Inc Rnai modulation of apob and uses thereof
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
WO2006044716A2 (en) 2004-10-15 2006-04-27 Washington University In St.Louis CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER
WO2006049983A2 (en) 2004-10-27 2006-05-11 Biorexis Pharmaceutical Corporation Peptide yy modified transferrin fusion proteins
AU2005304963C1 (en) 2004-11-04 2011-01-06 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
CA2629751A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
EP1657306B1 (en) 2004-11-16 2011-04-13 QIAGEN GmbH Gene silencing using sense DNA and antisense RNA hybrid constructs coupled to peptides facilitating the uptake into cells
US7772201B2 (en) 2004-11-17 2010-08-10 “University of Maryland, Baltimore” Highly branched HK peptides as effective carriers of siRNA
US20060134189A1 (en) 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
ITMI20042353A1 (it) 2004-12-10 2005-03-10 Uni Degli Studi Di Modena E Re Peptidi per la veicolazione di farmaci
CA2593956A1 (en) 2004-12-22 2006-06-29 Lipopeptide Ab Agents inhibiting the cathelin-like protein cap18/ll-37
US20080280781A1 (en) 2005-01-16 2008-11-13 Georgia Tech Research Corporation Methods and Compositions for Increasing Membrane Permeability
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086883A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
US8765116B2 (en) 2005-03-24 2014-07-01 Medifocus, Inc. Apparatus and method for pre-conditioning/fixation and treatment of disease with heat activation/release with thermoactivated drugs and gene products
KR100734525B1 (ko) 2005-05-27 2007-07-03 크레아젠 주식회사 인간 및 비근교계 동물에서 세포독성 ｔ 임파구 활성을효과적으로 측정하는 방법
CN103989633A (zh) 2005-07-27 2014-08-20 普洛体维生物治疗公司 制造脂质体的系统和方法
CN101292033B (zh) 2005-08-01 2013-04-03 普渡研究基金会 用于活性试剂向细胞的递送的多价rna纳粒
CN101517407A (zh) 2005-09-07 2009-08-26 纽约州州立大学研究基金会 用于研究动脉粥样硬化损害的动物模型
WO2008039173A2 (en) 2005-09-09 2008-04-03 Government Of The United States Of Amercica, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
CA2623841C (en) 2005-09-27 2019-03-12 National Research Council Of Canada Methods of identifying agents capable of tmem30a mediated transmigration across the blood brain barrier (bbb)
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20070160658A1 (en) 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
JP2009513158A (ja) 2005-11-01 2009-04-02 アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティ 新規タンパク質伝達ドメインおよびその使用
WO2007056153A2 (en) 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
ATE478676T1 (de) 2005-11-04 2010-09-15 Forhumantech Co Ltd Verfahren zur abgabe von fusionspolypeptid in eine zelle
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
US8242081B2 (en) 2005-12-06 2012-08-14 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
AU2006330769A1 (en) 2005-12-29 2007-07-05 Kansas State University Research Foundation Antimicrobial cathelicidin peptides
JP2009532017A (ja) 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
AU2007243412A1 (en) 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
WO2007133182A2 (en) 2006-04-28 2007-11-22 Robert Talmage Modular aerospace plane
DK2021472T3 (da) 2006-05-05 2011-09-19 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af genekspression
CN101484588B (zh) 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
WO2007131286A1 (en) 2006-05-16 2007-11-22 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
WO2007137117A2 (en) 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
GB2438205A (en) 2006-05-18 2007-11-21 Carl John Parker Fall cushioning device
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
CA2653444A1 (en) 2006-06-07 2007-12-13 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
WO2007148078A1 (en) 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
DE602007013559D1 (de) 2006-07-07 2011-05-12 Univ Aarhus Nanoteilchen zur abgabe von nukleinsäure
CA2659103C (en) 2006-07-12 2019-05-21 The Regents Of The University Of California Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
WO2008022046A2 (en) 2006-08-18 2008-02-21 Nastech Pharmaceutical Company Inc. Dicer substrate rna peptide conjugates and methods for rna therapeutics
JP5959795B2 (ja) 2006-08-18 2016-08-02 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 血液脳関門送達のための物質
BRPI0715375A2 (pt) 2006-08-18 2013-06-18 Hoffmann La Roche policonjugados para distribuiÇço in vivo de polinucleotÍdeos
NZ574758A (en) 2006-08-21 2012-03-30 Univ British Columbia Small cationic antimicrobial peptides
WO2008026224A2 (en) 2006-08-31 2008-03-06 University Of Hyderabad Novel nanoparticles of apotransferrin / transferrin, pharmaceutical composition containing them and processes for their preparation
EP2068832A2 (en) 2006-09-11 2009-06-17 Medtronic, Inc. Liposome complexes containing pharmaceutical agents and methods
WO2008033395A2 (en) 2006-09-14 2008-03-20 Biorexis Pharmaceutical Corporation Melanocortin and transferrin fusion proteins
WO2008033285A2 (en) 2006-09-15 2008-03-20 The Trustees Of Culumbia University In The City Of New York Delivery of double-stranded rna into the central nervous system
WO2008039188A1 (en) 2006-09-27 2008-04-03 Boston Scientific Corporation Method of treating cancer comprising introduction of heat and delivery of liposome containing an active agent or thermo-activated drug, gene or virus to tissue
US9211340B2 (en) 2006-09-27 2015-12-15 Paolo Botti Means and methods of enhancing delivery to biological systems
US20100004316A1 (en) 2006-09-29 2010-01-07 University Of Utah Research Foundation Multifunctional carriers for the delivery of nucleic acids and methods of use thereof
WO2008045486A2 (en) 2006-10-09 2008-04-17 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
WO2008043366A2 (en) 2006-10-13 2008-04-17 Københavns Universitet Three-domain compounds for transmembrane delivery
WO2008063113A1 (en) 2006-11-20 2008-05-29 Cepep Iii Ab Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
WO2008070141A2 (en) 2006-12-06 2008-06-12 Wisconsin Alumni Research Foundation Compositions for delivery of therapeutic agents
WO2008073856A2 (en) 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
ES2535358T3 (es) 2006-12-12 2015-05-08 Biorexis Pharmaceutical Corporation Bibliotecas de proteínas de fusión de transferrina
WO2008091465A2 (en) 2006-12-21 2008-07-31 Wayne State University Peg and targeting ligands on nanoparticle surface
AU2008211854C1 (en) 2007-01-29 2014-01-23 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
WO2008094516A2 (en) * 2007-01-29 2008-08-07 City Of Hope Multi-targeting short interfering rnas
US20080187998A1 (en) 2007-02-01 2008-08-07 University Of Utah Research Foundation Sulfonamide-based oligomers and polymers for destabilization of biological membranes
EP1955695A1 (en) 2007-02-06 2008-08-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nanocapsules of lipophilic complexes of nucleic acids
US20130177598A1 (en) 2007-02-27 2013-07-11 The University Of North Carolina At Chapel Hill Discrete size and shape specific pharmaceutical organic nanoparticles
RU2559536C2 (ru) 2007-03-24 2015-08-10 Джензим Корпорейшн Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
ATE479250T1 (de) 2007-04-17 2010-09-15 Alcatel Lucent Verfahren und vorrichtung zur reservierung von netzwerkressourcen für eine punkt-zu-punkt- pseudoverbindung
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009035438A1 (en) 2007-09-13 2009-03-19 Janos Borbely Polymeric nanoparticles by ion-ion interactions
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference

Also Published As

Publication number Publication date
EP2488210A2 (en) 2012-08-22
EP3252068A3 (en) 2018-03-14
AU2021200888A1 (en) 2021-03-04
WO2011046983A3 (en) 2011-06-09
WO2011046983A2 (en) 2011-04-21
US20130079382A1 (en) 2013-03-28
EP3252068A2 (en) 2017-12-06
AU2019200947A1 (en) 2019-02-28
AU2017200198A1 (en) 2017-03-30
EP4089169A1 (en) 2022-11-16
CA2780741C (en) 2023-04-04
AU2019200947B2 (en) 2020-11-12
EP2488210A4 (en) 2014-04-30
EP3252068B1 (en) 2025-07-02
CA2780741A1 (en) 2011-04-21
AU2010306940A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
IL276157A (en) Pharmaceutical preparations and methods for transferring them related to them
IL276146A (en) Laboratory methods for increasing the vitality of the cells of the immune system
DK2493474T3 (da) Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler
IL251161B (en) Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
EP2488210A4 (en) METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS
DK3278665T3 (da) Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
DK2506896T3 (da) Anordning og fremgangsmåde til afgivelse af to eller flere lægemidler
DK2532366T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2275086T3 (da) Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
DK2254590T3 (da) Fremgangsmåder og præparater til oral administration af insulin
IL220465A0 (en) Methods and compositions for stable liquid drug formulations
EP2453905A4 (en) METHOD AND COMPOSITIONS ON CHONDROGENESIS IN VITRO AND VIVO
IL208147A (en) Pleuvirus without replication, nucleic acid molecule, composition of pharmacy, its use and method of production
HUE041426T2 (hu) Terápiás nukleáz-készítmények és eljárások
DK3109326T3 (da) Sammensætning og fremgangsmåde til nukleinsyresyntese og amplifikation under anvendelse af rt
DK3834841T3 (da) Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
HUP1000407A2 (en) Ph dependent pulsatile and sustained release pharmaceutical composition
DK2501771T3 (da) Fugtighedshærdbare polyamider og fremgangsmåder til deres fremstilling
DK2266596T3 (da) Farmaceutisk sammensætning og fremgangsmåde til fremstilling deraf
EP2171069A4 (en) INTRODUCTION OF NUCLEIC ACIDS IN HUMAN STEM CELL GENOMES USING IN VITRO ASSEMBLED MU TRANSPOSITION COMPLEXES
IL201228A0 (en) Methods of gene amplification and expression